The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Leukemia Therapeutics Market Over The 2026–2030 Period?
The leukemia therapeutics market size has experienced robust expansion in recent years. It is projected to grow from $18.67 billion in 2025 to $20.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. The historical growth observed in this market can be attributed to factors such as rising leukemia incidence rates, the development of first-generation chemotherapy drugs, increased healthcare expenditure in developed regions, advancements in bone marrow transplantation, and growth in biologics research.
The leukemia therapeutics market is projected to experience robust expansion over the coming years, anticipated to reach a valuation of $27.41 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This projected growth is driven by several factors, including the increasing use of CAR T-cell therapies, the implementation of precision medicine strategies, the incorporation of artificial intelligence into treatment planning, the rise of homecare treatment options, and the creation of innovative targeted therapies. Key developments expected during this period encompass tailored leukemia treatment plans, the integration of sophisticated diagnostic methods, the broadening availability of outpatient and home-based treatments, the evolution of combination therapies, and a heightened focus on rare and drug-resistant forms of leukemia.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6358&type=smp
Which Economic Or Industry Drivers Are Impacting The Leukemia Therapeutics Market?
The increasing occurrence of leukemia is propelling the expansion of the leukemia therapeutics market. Leukemia, a form of blood cancer originating in the bone marrow, progresses to uncontrolled proliferation of blood cells. Enhanced access to medical care for leukemia sufferers worldwide, coupled with an expanding array of treatment options, has boosted the need for leukemia therapeutics. For example, in January 2023, data from a report by the American Cancer Society, a US-based health organization, projected roughly 59,610 new instances of all types of leukemia and approximately 23,710 deaths in 2023 due to all types of leukemia in the United States. Furthermore, the same year is expected to see an estimated 20,380 new acute myeloid leukemia (AML) cases and about 11,310 AML-related fatalities. Consequently, the growing prevalence of leukemia is contributing to the growth of the leukemia therapeutics market.
How Is The Leukemia Therapeutics Market Segmented Across Key Categories?
The leukemia therapeutics market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids
2) By Immunotherapy: Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines
3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents
4) By Other Treatments: Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments
Which Upcoming Trends Are Expected To Influence The Leukemia Therapeutics Market?
Leading firms within the leukemia therapeutics market are creating novel products like CAR T therapies, aiming to attract more customers, boost sales, and generate higher revenue. Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a revolutionary type of immunotherapy utilized in treating specific forms of cancer. As an example, in March 2024, Bristol-Myers Squibb Company, a pharmaceutical firm based in the US, reported that Breyanzi (lisocabtagene maraleucel; liso-cel) had received approval from the US Food and Drug Administration (FDA). This particular treatment is a CD19-directed chimeric antigen receptor (CAR) T cell therapy intended for adult patients suffering from relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received at least two prior treatment regimens, which encompassed both a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
Who Are The Dominant Players Shaping The Leukemia Therapeutics Market Landscape?
Major companies operating in the leukemia therapeutics market are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.
Read the full leukemia therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
What Are The Top-Performing Regions Within The Leukemia Therapeutics Market?
North America was the largest region in the leukemia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Leukemia Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=6358&type=smp
Browse Through More Reports Similar to the Global Leukemia Therapeutics Market 2026, By The Business Research Company
Leukemia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Leqembi Market Report 2026
https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report
Chronic Myeloid Leukemia Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model